Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus

Wild, 2004, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Ruggenenti, 2004, Preventing microalbuminuria in type 2 diabetes, N Engl J Med, 351, 1941, 10.1056/NEJMoa042167 Caramori, 2003, Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions, Diabetes, 52, 1036, 10.2337/diabetes.52.4.1036 Fioretto, 1998, Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure, Diabetologia, 41, 233, 10.1007/s001250050895 Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Vilayur, 2009, Emerging therapies for chronic kidney disease: what is their role?, Nat Rev Nephrol, 5, 375, 10.1038/nrneph.2009.76 Allendorph, 2006, Structure of the ternary signaling complex of a TGF-beta superfamily member, Proc Natl Acad Sci USA, 103, 7643, 10.1073/pnas.0602558103 Sharma, 1996, Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice, Diabetes, 45, 522, 10.2337/diab.45.4.522 Ziyadeh, 1994, Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta, J Clin Invest, 93, 536, 10.1172/JCI117004 Sharma, 1997, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes, Diabetes, 46, 854, 10.2337/diab.46.5.854 Hellmich, 2000, Activation of transforming growth factor-beta1 in diabetic kidney disease, Metabolism, 49, 353, 10.1016/S0026-0495(00)90264-6 Zeisberg, 2006, Bone morphogenic protein-7 and the kidney: current concepts and open questions, Nephrol Dial Transplant, 21, 568, 10.1093/ndt/gfk010 Gould, 2002, BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells, Kidney Int, 61, 51, 10.1046/j.1523-1755.2002.00103.x Wang, 2003, BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells, Am J Physiol Renal Physiol, 284, F1006, 10.1152/ajprenal.00382.2002 Zeisberg, 2003, BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury, Nat Med, 9, 964, 10.1038/nm888 Zeisberg, 2003, Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models, Am J Physiol Renal Physiol, 285, F1060, 10.1152/ajprenal.00191.2002 Wang, 2001, Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy, J Am Soc Nephrol, 12, 2392, 10.1681/ASN.V12112392 Wang, 2003, Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy, Kidney Int, 63, 2037, 10.1046/j.1523-1755.2003.00035.x Wang, 2006, Renal bone morphogenetic protein-7 protects against diabetic nephropathy, J Am Soc Nephrol, 17, 2504, 10.1681/ASN.2006030278 Dudas, 2009, BMP-7 fails to attenuate TGF-beta1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells, Nephrol Dial Transplant, 24, 1406, 10.1093/ndt/gfn662 Patel, 2007, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet, 370, 829, 10.1016/S0140-6736(07)61303-8 Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987 Liu, 2011, Cellular and molecular mechanisms of renal fibrosis, Nat Rev Nephrol, 7, 684, 10.1038/nrneph.2011.149 Boon, 2011, Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency, Cytokine Growth Factor Rev, 22, 221, 10.1016/j.cytogfr.2011.08.001 Bohle, 1987, Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution, Am J Nephrol, 7, 421, 10.1159/000167514 Nath, 1992, Tubulointerstitial changes as a major determinant in the progression of renal damage, Am J Kidney Dis, 20, 1, 10.1016/S0272-6386(12)80312-X Suthanthiran, 2000, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage, Proc Natl Acad Sci USA, 97, 3479 Suthanthiran, 2009, Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans, Kidney Int, 76, 72, 10.1038/ki.2009.66 Zitouni, 2005, Circulating vitamin E, transforming growth factor beta1, and the association with renal disease susceptibility in two racial groups with type 2 diabetes, Kidney Int, 67, 1993, 10.1111/j.1523-1755.2005.00300.x August, 2003, Transforming growth factor beta and progression of renal disease, Kidney Int Suppl, S99, 10.1046/j.1523-1755.64.s87.15.x Sharma, 1999, Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients, Am J Kidney Dis, 34, 818, 10.1016/S0272-6386(99)70037-5 Lund, 2004, Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model, J Am Soc Nephrol, 15, 359, 10.1097/01.ASN.0000109671.99498.08 Sharma, 2011, Pirfenidone for diabetic nephropathy, J Am Soc Nephrol, 22, 1144, 10.1681/ASN.2010101049 Soma, 2006, Effect of tranilast in early-stage diabetic nephropathy, Nephrol Dial Transplant, 21, 2795, 10.1093/ndt/gfl325 Soma, 2002, Tranilast slows the progression of advanced diabetic nephropathy, Nephron, 92, 693, 10.1159/000064071 Lizakowski, 2012, Aliskiren and perindopril reduce the levels of transforming growth factor-beta in patients with non-diabetic kidney disease, Am J Hypertens, 25, 636, 10.1038/ajh.2012.14 Benigni, 2003, Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat, J Am Soc Nephrol, 14, 1816, 10.1097/01.ASN.0000074238.61967.B7 Collaborative Study Group (CSG) ELaC Chalmers, 2010, Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE, J Cardiovasc Pharmacol, 55, 340, 10.1097/FJC.0b013e3181d26469 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006 Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002 Akaike, 1974, A new look at the statistical model identification, IEEE Trans Automat Contr, 6, 716, 10.1109/TAC.1974.1100705 Schwarz, 1978, Estimating the dimension of a model, Ann Statist, 2, 461, 10.1214/aos/1176344136